How Much Does Semaglutide Cost? (2026 Guide)

Semaglutide Cost at a Glance

Semaglutide is sold under two major brand names — Ozempic® (for type 2 diabetes) and Wegovy® (for chronic weight management) — and is also available in compounded form through licensed telehealth providers. What you pay depends heavily on which route you take and whether you have qualifying insurance coverage.

• Brand-name Wegovy® (no insurance): approximately $1,350–$1,450 per month
• Brand-name Ozempic® (no insurance): approximately $900–$1,000 per month
• Compounded semaglutide (telehealth): typically $150–$350 per month, with introductory offers starting lower at AvataCore

See AvataCore pricing → for current plans and dosing details.

Why Is Brand-Name Semaglutide So Expensive?

Semaglutide is manufactured exclusively by Novo Nordisk, which holds the patents on the molecule and its formulations. Without meaningful insurance coverage — which the majority of Americans seeking weight-loss treatment lack — patients pay close to full retail price. Even for patients with insurance, prior authorization requirements, step therapy mandates, and inconsistent plan coverage create significant barriers and out-of-pocket costs.

The contrast with compounded semaglutide is stark. When semaglutide was placed on the FDA's drug shortage list, licensed compounding pharmacies became legally permitted to prepare customized versions — and the price difference reflects the absence of brand-name markup and manufacturer R&D cost recovery. See our compounded semaglutide guide for a full explanation of the compounded pathway.

Does Insurance Cover Semaglutide?

Ozempic (Diabetes Indication)

Coverage for Ozempic® as a type 2 diabetes treatment is relatively common across commercial insurance plans and Medicaid in many states, though prior authorization is almost always required. Patients with a confirmed type 2 diabetes diagnosis have the best odds of coverage. Medicare Part D covers Ozempic for diabetes.

Wegovy (Weight Management)

Coverage for Wegovy® is inconsistent and often unavailable. Many commercial health plans explicitly exclude weight-loss medications. Medicare does not cover medications prescribed solely for weight loss, though coverage has expanded for specific cardiovascular risk reduction indications since the SELECT trial results. State Medicaid programs vary widely — some cover Wegovy, most do not.

Even when Wegovy is covered, high deductibles, co-insurance, and quantity limits mean patients often pay several hundred dollars per month even with insurance.

HSA and FSA: Reduce Your Effective Cost with Pre-Tax Dollars

If you have a Health Savings Account (HSA) or Flexible Spending Account (FSA), you can pay for prescribed semaglutide — including compounded versions — and associated telehealth visits with pre-tax dollars. For someone in the 22% federal tax bracket, every $1,000 in HSA/FSA spending effectively costs $780. That is a meaningful real-world discount on top of whatever route you choose.

To qualify for HSA/FSA reimbursement, the medication must be prescribed by a licensed provider. All AvataCore prescriptions are issued by licensed healthcare professionals, making your GLP-1 treatment eligible for pre-tax health account spending.

Compounded Semaglutide: The Cost-Effective Alternative

Compounded semaglutide is prepared by a state-licensed compounding pharmacy in response to a valid prescription from a licensed provider. It is different from FDA-approved branded products such as Wegovy® and Ozempic® and has not been evaluated by the FDA for safety, efficacy, or quality. Formulation, inactive ingredients, and clinical effects may differ from the FDA-approved branded versions. Compounded medications are not FDA-approved.

The primary advantage is cost. For patients without qualifying insurance coverage — which is the majority of the weight-loss semaglutide market — the difference between $1,350/month for Wegovy and $150–$350/month for compounded semaglutide is the difference between treatment being accessible and not accessible at all.

Wegovy Savings Programs and Manufacturer Coupons

Novo Nordisk offers a savings program for commercially insured patients that can reduce out-of-pocket costs for Wegovy. However, this program typically applies only to those with commercial insurance (not Medicare or Medicaid) and has income and eligibility requirements. For patients who qualify, this can reduce costs substantially — but the majority of uninsured or government-insured patients do not qualify.

Semaglutide vs Tirzepatide: Which Is More Affordable?

Tirzepatide (the active ingredient in Mounjaro® and Zepbound®) is the other major GLP-1 option for weight management. While brand-name tirzepatide carries similar pricing to brand-name semaglutide ($1,000–$1,400/month), compounded tirzepatide is also available at comparable cost-accessible pricing to compounded semaglutide.

The clinical consideration: tirzepatide has shown higher average weight loss in head-to-head comparison data. AvataCore offers both compounded semaglutide and compounded tirzepatide. Our providers can help you determine which is the better fit for your goals, health history, and tolerance profile. See our semaglutide vs tirzepatide comparison and our tirzepatide cost guide for more detail.

What About Costs Beyond the Medication?

When evaluating total cost of a GLP-1 program, it is worth considering what is included beyond the medication itself:

• Provider visit fees: Some providers charge separately for the initial consultation and ongoing follow-up appointments. At AvataCore, clinical monitoring is included in the program.
• Labs: Depending on your health history, a provider may recommend baseline labs (blood glucose, lipids, kidney function). These may be covered by your health insurance under preventive care.
• Injection supplies: Syringes and needles for compounded semaglutide preparations are typically low-cost and readily available at pharmacies.

The Bottom Line on Semaglutide Cost

For patients with qualifying commercial insurance, brand-name semaglutide (Wegovy or Ozempic) paired with a manufacturer savings program can be surprisingly accessible. For the majority of patients — those without adequate coverage or on government insurance — compounded semaglutide through a licensed telehealth provider is the primary realistic option at $150–$350 per month.

If you have an HSA or FSA, use it: the pre-tax advantage adds meaningful real-world savings regardless of which route you choose. See AvataCore pricing for current plans, or our broader GLP-1 cost overview for the full landscape across medications.